Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – August 4, 2025 – Khondrion announced that the European Commission has granted Orphan Drug Designation (ODD) to its lead investigational therapy, sonlicromanol, for the treatment of all inherited mitochondrial oxidative phosphorylation (OXPHOS) defects.
Khondrion, a clinical-stage biopharmaceutical companypioneering therapies for primary mitochondrial disease (PMD), today announced it has beenawarded an Innovation Credit of up to €5 million from the Netherlands Enterprise Agency, agovernment agency that supports entrepreneurs...
The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion...
52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...
Khondrion, a clinical-stage biopharmaceutical company specializing in mitochondrial disease therapies,...
Primary Mitochondrial Diseases (PMDs) are a group of conditions that usually affect multiple organs and systems in the body. They are caused by problems in the mitochondria—the parts of our cells that produce energy...
Jan Smeitink: Serving the Mitochondrial Medicine Mission Embarking on the journey of biopharmaceutical innovation demands more than just...
Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation (UMDF) Bench to Bedside...
2022 – A Year in Review As 2022 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the significant progress achieved by Khondrion in its...
How did you first become involved with the mitochondrial disease community and MitoCanada? I joined MitoCanada at a very exciting time, two months...
How did you first become involved with the mitochondrial disease community and what led you to the Mito Foundation? I first learnt of mitochondrial...
